Neoadjuvant Therapy in Differentiated Thyroid Cancer

Table 1

Select studies of chemotherapy in metastatic differentiated thyroid cancer.

Author and year	Sample size	Intervention	Response
Gottlieb et al., 1972 [5]	6 with DTC.	Various single and combination agents, including doxorubicin.	33.3% PR.
Gottlieb and Hill, 1974 [6]	15 with DTC.	Doxorubicin at 45, 60, or 75 mg/m^2 IV.	33.3% PR.
Matuszczyk et al., 2008 [7]	22 with DTC.	Doxorubicin at 15 mg/m^2 IV weekly or 60 mg/m^2 IV every 3 weeks.	5% PR, 42% SD, 53% PD.
Williams et al., 1986 [8]	22 with advanced thyroid cancer of all histological subtypes.	Doxorubicin 60 mg/m^2 plus cisplatin 60 mg/m^2.	9.1% PR.
Shimaoka  et al., 1985 [9]	35 with DTC.	Doxorubicin 60 mg/m^2 with cisplatin 40 mg/m^2 or doxorubicin alone.	16% and 31% ORR for combination and monotherapy, respectively.
Matuszczyk et al., 2010 [10]	7 with DTC.	Paclitaxel 90–100 mg/m^2 and gemcitabine 1000 mg/m^2.	No responses observed.

Definitions: DTC: differentiated thyroid cancer, MTC: medullary thyroid cancer, ORR: overall response rate, PD: progressive disease, PR: partial response, and SD: stable disease.
Results for both doses (15 mg/m² IV weekly or 60 mg/m² IV every 3 weeks).